Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Conservative estimate: 28 days refrigerated at 2-8 degrees Celsius (36-46 degrees Fahrenheit) Extended estimate: Up to 60 days under ideal storage conditions At low doses, the math does not work
(J Appl Toxicol, 2010) compared healing rates in standardized skin wounds
MOTS-c MOTS-c was evaluated for obesity and osteoporosis and received a 7-5 favorable vote with two abstentions
Commonly used in non-clinical research to track changes in tissue-response markers, barrier integrity, and signaling readouts over time (in-vitro and animal models)
Oxidative damage is attributed to diseases such as: Lou Gerhigs Disease (ALS), Parkinsons disease Autism Multiple Sclerosis Alzheimers Dementia Huntingtons Disease Cardiovascular Disease Chronic Fatigue Syndrome Cancer Diabetes Macular Degeneration Aging Liver Disease Skin Disorders Lung Disease ETC
Why Compounding Access Is Not an Established Path Positioning in the Metabolic Medicine Conversation For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing: Promising mechanism with solid preclinical rationale Early clinical development human efficacy and safety not yet well characterized No legitimate clinical access pathway in the United States as of 2026 Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue Key Takeaways 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide
US$ 24.48
US$ 23.70
US$ 28.36
US$ 27.00
